Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brief R-BM Chemoimmunotherapy in Elderly Follicular Lymphoma
NCT01523860Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jun 2009
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, bendamustine and mitoxantrone in follicular lymphoma (FL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Complete Response Rate at 6 months. Started Jun 2009; status: completed.
02
Drugs
rituximabbendamustinemitoxantrone
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01523860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01523860.